Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute
In December 2021, Apple Tree Partners (ATP), a leader in life sciences venture capital, announced the launch of Adendra Therapeutics Ltd, a spin-out of immunology research by Crick Principal Group Leader Caetano Reis e Sousa and his team. One year on, Caetano explains why working with ATP on early stage discovery research in his lab has been key to the early success of Adendra.
